Casdin Partners Master Fund, L.P.

Director at 2seventy bio, Inc. · on record since Mar 28, 2024
10% owner at Verve Therapeutics, Inc. · on record since Jun 22, 2021
Director at GeneDx Holdings Corp. · on record since May 11, 2026
10% owner at GeneDx Holdings Corp. · on record since May 11, 2026
10% owner at BIOLIFE SOLUTIONS INC · on record since May 21, 2026
10% owner at CONSTAR INTERNATIONAL INC · on record since Jul 23, 2018
10% owner at Fulcrum Therapeutics, Inc. · on record since Jul 22, 2019
10% owner at MAXCYTE, INC. · on record since Jul 30, 2021
10% owner at Tenaya Therapeutics, Inc. · on record since Jul 29, 2021
10% owner at Decibel Therapeutics, Inc. · on record since Feb 19, 2021
Director at Absci Corp · on record since Jul 28, 2021
10% owner at Absci Corp · on record since Jul 21, 2021
Director at LABRANCHE & CO INC · on record since Apr 6, 2022
10% owner at LABRANCHE & CO INC · on record since Apr 6, 2022

Insider trading activity of Casdin Partners Master Fund, L.P.

Transactions on record: 38; since Jul 22, 2019

Open-market buys: 22; $57.3M

Open-market sells: 3; $28.1M

Companies traded: 6; last filing May 21, 2026

Figures computed from official regulatory filings — .

Companies where Casdin Partners Master Fund, L.P. has traded

BIOLIFE SOLUTIONS INC14 tx · $55M · May 21, 2026
LABRANCHE & CO INC8 tx · $1.9M · Nov 17, 2025
3 tx · $13.7M · Aug 5, 2024
5 tx · $20.9M · Jun 22, 2021
3 tx · $10.4M · Feb 19, 2021
5 tx · $2.2M · Jul 22, 2019

Track record of Casdin Partners Master Fund, L.P.

Statistical track record

Free

Open-market buys: 22

Last buy: Nov 17, 2025

Win rates and median returns are available with a free account (5 insiders/month).

Transaction history of Casdin Partners Master Fund, L.P.

Co-insiders of Casdin Partners Master Fund, L.P.

This page republishes public regulatory disclosures.

Company	Filed	Type	Qty	Price	Value · USD	Src
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-650,000	23.70 USD	$15.4M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-250,000	23.70 USD	$5.9M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-300,000	22.65 USD	$6.8M	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	250,000	1.24 USD	$310K	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	450,000	1.20 USD	$540K	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	225,000	1.22 USD	$274.5K	SEC
LABRANCHE & CO INCListing unverified	Sep 11, 2025	Buy	100,000	1.29 USD	$129K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	200,000	1.24 USD	$248K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	125,000	1.26 USD	$157.5K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	200,000	1.26 USD	$252K	SEC
GeneDx Holdings Corp.Listing on record	Aug 5, 2024	Other	413,655	32.25 USD	$13.3M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 2, 2024	Other	150,000	17.54 USD	$2.6M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 2, 2024	Other	-150,000	17.54 USD	$2.6M	SEC
GeneDx Holdings Corp.Listing on record	Mar 6, 2024	Buy	40,000	8.74 USD	$349.6K	SEC
GeneDx Holdings Corp.Listing on record	Mar 6, 2024	Buy	900	8.83 USD	$7.9K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 19, 2023	Other	131,428	—	—	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	15,000	20.19 USD	$302.9K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	30,027	21.30 USD	$639.6K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	30,000	21.76 USD	$652.8K	SEC
LABRANCHE & CO INCListing unverified	Apr 6, 2022	AwardD (derivative)	127,780	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Buy	1,100,000	19.00 USD	$20.9M	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Other	310,285	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	OtherD (derivative)	-2,873,091	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	OtherD (derivative)	-9,327,198	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Other	1,007,311	—	—	SEC

Company	Filed	Type	Qty	Price	Value · USD	Src
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-650,000	23.70 USD	$15.4M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-250,000	23.70 USD	$5.9M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 21, 2026	Sell	-300,000	22.65 USD	$6.8M	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	250,000	1.24 USD	$310K	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	450,000	1.20 USD	$540K	SEC
LABRANCHE & CO INCListing unverified	Nov 17, 2025	Buy	225,000	1.22 USD	$274.5K	SEC
LABRANCHE & CO INCListing unverified	Sep 11, 2025	Buy	100,000	1.29 USD	$129K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	200,000	1.24 USD	$248K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	125,000	1.26 USD	$157.5K	SEC
LABRANCHE & CO INCListing unverified	Aug 26, 2025	Buy	200,000	1.26 USD	$252K	SEC
GeneDx Holdings Corp.Listing on record	Aug 5, 2024	Other	413,655	32.25 USD	$13.3M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 2, 2024	Other	150,000	17.54 USD	$2.6M	SEC
BIOLIFE SOLUTIONS INCListing on record	May 2, 2024	Other	-150,000	17.54 USD	$2.6M	SEC
GeneDx Holdings Corp.Listing on record	Mar 6, 2024	Buy	40,000	8.74 USD	$349.6K	SEC
GeneDx Holdings Corp.Listing on record	Mar 6, 2024	Buy	900	8.83 USD	$7.9K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 19, 2023	Other	131,428	—	—	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	15,000	20.19 USD	$302.9K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	30,027	21.30 USD	$639.6K	SEC
BIOLIFE SOLUTIONS INCListing on record	May 18, 2023	Buy	30,000	21.76 USD	$652.8K	SEC
LABRANCHE & CO INCListing unverified	Apr 6, 2022	AwardD (derivative)	127,780	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Buy	1,100,000	19.00 USD	$20.9M	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Other	310,285	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	OtherD (derivative)	-2,873,091	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	OtherD (derivative)	-9,327,198	—	—	SEC
Verve Therapeutics, Inc.Listing unverified	Jun 22, 2021	Other	1,007,311	—	—	SEC